Acquisition by Scott Smith of 92503 shares of Viatris subject to Rule 16b-3
| VTRS Stock | USD 10.36 0.09 0.88% |
Slightly above 53% of Viatris' investor base is interested to short. The analysis of overall sentiment of trading Viatris stock suggests that many investors are impartial at this time. Viatris' investing sentiment can be driven by a variety of factors including economic data, Viatris' earnings reports, geopolitical events, and overall market trends.
Filed transaction by Viatris Director, Officer Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Viatris Fundamental Analysis
We analyze Viatris' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viatris using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viatris based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Viatris is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Viatris Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Viatris stock to make a market-neutral strategy. Peer analysis of Viatris could also be used in its relative valuation, which is a method of valuing Viatris by comparing valuation metrics with similar companies.
Peers
Viatris Related Equities
| NBIX | Neurocrine Biosciences | 3.75 | ||||
| EXAS | EXACT Sciences | 2.33 | ||||
| ROIV | Roivant Sciences | 2.09 | ||||
| RGC | Regencell Bioscience | 1.83 | ||||
| IONS | Ionis Pharmaceuticals | 0.18 | ||||
| BBIO | BridgeBio Pharma | 1.15 | ||||
| RDY | Dr Reddys | 1.19 | ||||
| ELAN | Elanco Animal | 1.86 | ||||
| MRNA | Moderna | 3.48 | ||||
| BAX | Baxter International | 3.60 |
Additional Tools for Viatris Stock Analysis
When running Viatris' price analysis, check to measure Viatris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viatris is operating at the current time. Most of Viatris' value examination focuses on studying past and present price action to predict the probability of Viatris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viatris' price. Additionally, you may evaluate how the addition of Viatris to your portfolios can decrease your overall portfolio volatility.